Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Adenocarcinoma × Lead × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 2 Stomatitis 1 Rectal Neoplasms 1 Periodontitis 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Head and Neck Neoplasms 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Febrile Neutropenia 1 EGFR-Mutant Lung Cancer 1 Deglutition Disorders 1 Communication Disorders 1 Colorectal Neoplasms 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Breast Neoplasms 1 Brain Neoplasms 1 Adenocarcinoma 1

Interventions

Oxaliplatin 42 Gemcitabine 41 Fluorouracil 37 Capecitabine 29 pembrolizumab 28 Leucovorin 26 Docetaxel 25 Cisplatin 24 Paclitaxel 21 Carboplatin 18 Bevacizumab 17 Irinotecan 16 130-nm albumin-bound paclitaxel 16 Pemetrexed 15 Radiotherapy 13 Albumin-Bound Paclitaxel 13 Nivolumab 12 Cyclophosphamide 10 Ramucirumab 9 Trastuzumab 7 Radiosurgery 7 cemiplimab 6 Taxes 6 Erlotinib Hydrochloride 6 Drug Therapy 6 zolbetuximab 5 trastuzumab deruxtecan 5 durvalumab 5 Sorafenib 5 S 1 (combination) 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01808638 2016-03-11

Atu027-I-02

Silence Therapeutics GmbH

Phase 1/2 Completed

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡